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OBJECTIVES The study objective was to clarify in a randomized, controlled, observer-blind trial whether
hormone replacement therapy (HRT) improves elastic properties of the common carotid
artery in women with signs of subclinical atherosclerosis, especially in subgroups with
increased risk, and whether less progestin enhances the effect.
BACKGROUND Previous observational studies have yielded conflicting results on the influence of HRT on
central arteries. Some studies reported improvement of distensibility by estrogen alone or in
the subgroup of smokers.
METHODS A total of 321 postmenopausal women were randomized to 1 mg 17b-estradiol plus 0.025 mg
gestodene for 12 days every month (HRT 1), or 1 mg 17b-estradiol plus 0.025 mg gestodene
for 12 days every third month (HRT 2), or no-HRT, during 48 weeks. In 173 women,
distensibility of the common carotid artery was determined before and after therapy by
M-mode ultrasound and brachial blood pressure measurement.
RESULTS Change of distensibility was small and similar in the three treatment groups. In the subgroup
of current smokers, HRT 2 (low progestin) increased distensibility by 32% (HRT 2: 8.2 6
11.7; HRT 1: 0.6 6 6.0; no HRT: 21.8 6 6.8 3 1023/kPa, p 5 0.025 for no-HRT vs. HRT
2). In the subgroups with elevated blood pressure, high low density lipoprotein (LDL)
cholesterol, or high age, no effect of HRT was detected.
CONCLUSIONS This randomized intervention study demonstrates that long-term HRT with estrogen and
progestin does not substantially influence distensibility of central arteries. Yet, in currently
smoking postmenopausal women, HRT with low progestin seems to improve distensibility;
this merits further study in a specifically designed trial. (J Am Coll Cardiol 2000;36:
1789–96) © 2000 by the American College of Cardiology
Distensibility, the inverse of stiffness, denotes the ability of
an artery to expand as a response to pulse pressure (1).
Independently from established risk factors, low distensibil-
ity of central elastic arteries, mainly aorta and common
carotid artery, is related to a high risk of future all-cause and
cardiovascular mortality in high-risk patients (2) and the
development of hypertension in the normal population (3).
Furthermore, a wide pulse pressure, which is largely deter-
mined by arterial stiffness (1), is an independent predictor of
coronary heart disease (CHD) morbidity, CHD mortality,
and all-cause mortality in healthy populations (4,5) and in
patients with CHD (6). Distensibility of central arteries can
be determined noninvasively in the common carotid artery
(CCA) by means of ultrasound and brachial blood pressure
measurement (7,8). This method has been widely used to
identify persons at risk for hypertension and CHD (3,9,10).
During menopause, distensibility of aorta and CCA
decreases rapidly (11,12). The influence of hormone re-
placement therapy (HRT) on these arteries has been the
objective of several epidemiological studies with inconsis-
tent results (13–18). Notably, whereas studies found no
difference in distensibility between HRT users and controls
in the entire sample, distensibility in estrogen users was
significantly higher compared to estrogen plus progestin
users (14,16) and in smokers on HRT compared to smokers
not on HRT (16,19).
The aim of the present randomized, controlled, one-year
intervention trial was to investigate the influence of HRT
on the distensibility of central arteries in postmenopausal
women with increased carotid intima media thickness
(IMT) as sign of preclinical atherosclerosis. Based on
findings of previous studies (20,21) it was assumed that
HRT beneficially influences distensibility, that HRT with
low progestin has a larger effect than HRT with high
progestin and that the improvement is strongest in subjects
with high CHD risk (high low density lipoprotein [LDL]
cholesterol, high blood pressure, older age, smokers).
METHODS
Subjects. Between March 1995 and September 1996,
women living in and near Munich were informed by various
media (Fig. 1) of the HRT study. They were elegible if they
were between 40 and 70 years of age, had passed natural or
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surgical menopause for at least one year or had follicle
stimulating hormone (FSH) levels .40 IU/liter in case they
were hysterectomized, had more than 1 mm IMT in at least
one of the predefined segments of the carotid arteries and
gave written informed consent. Women with myocardial
infarction within the last six months, CHD that required
treatment for angina, or any other contraindication against
HRT, as well as women with conditions requiring HRT,
were not elegible. The study was approved by the local
ethics committee of the Faculty of Medicine of the Univer-
sity of Munich. It was conducted according to the Interna-
tional Conference for Harmonization–Guidelines for Good
Clinical Practice (ICH–GCP). An independent clinical
research organization (Biometrisches Zentrum fu¨r Therapi-
estudien, Munich, Germany) monitored adherence to the
study protocol, verified all source data and provided the
verified database. Members provided and maintained com-
puter software for randomization at the trial center and
ensured blinding of the ultrasound reader.
Study design and treatment. This study was embedded in
the Postmenopausal HOrmone REplacement against Ath-
erosclerosis (PHOREA) trial, which was a randomized,
controlled, observer-blind, single-center study. The primary
outcome measure of the present study was the change of
distensibility ([DC] distensibility coefficient) within 48
weeks, comparing each of the HRT groups with the
no-HRT group. Secondary outcome measures were the
change of DC in the following four subgroups: age greater
than median; LDL greater than median; elevated blood
pressure (mean of three measurements during M-mode:
either diastolic .90 or systolic .140 mm Hg); current
smokers.
Subjects were randomized to three groups: The HRT
group with standard (high) dose progestin (5 HRT 1)
received tablets containing 1 mg of 17b-estradiol daily, with
addition of 0.025 mg gestodene on days 17 to 28 of each
four-week cycle. The HRT group with low-dose progestin
(HRT 2) differed from HRT 1 in that gestodene was added
in each third cycle only. The no-HRT group received no
estrogen or progestin, also excluding topical application.
The duration of treatment was 48 weeks (12 cycles).
Women were seen as outpatients at study start, and in weeks
12, 22 and 48. At each visit, history, medication, behavioral
Abbreviations and Acronyms
BMI 5 body mass index
CCA 5 common carotid artery
CHD 5 coronary heart disease
DC 5 distensibility coefficient
ECG 5 electrocardiogram
FSH 5 follicle stimulating hormone
HRT 5 hormone replacement therapy
IMT 5 intima media thickness
LDL 5 low density lipoprotein cholesterol
Figure 1. Trial profile. HRT 5 hormone replacement therapy; IMT 5 intima media thickness.
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risk factors and adverse events were documented, and an
extended laboratory workup was carried out. General health
advice and treatment of hypertension and of elevated LDL
followed the guidelines of the American Heart Association
(22). The study medication was dispensed at each visit, and
all blisters and all remaining tablets were collected during
the subsequent visits. In a diary, subjects documented both
daily intake of the study drug and vaginal bleeding.
Randomization and blinding. Subjects were randomized
in two strata according to whether they had 0 to 2, or more
than two, cardiovascular risk factors in order to ensure their
even distribution. To ensure blindness of sonographers with
respect to treatment, their contact with the participant was
limited to the ultrasound examination. On all recordings a
five-digit random number replaced the name of the subject
and the date of examination. The keyed list containing
names, dates and five-digit numbers was kept at the monitor
until the closing of the file.
Ultrasound examination. At baseline, the carotid arteries
of all subjects were visualized in B-mode and M-Mode by
means of a high-resolution 7.5-MHz ultrasound (Apogee
CX Color, ATL, Bothel, Washington). First, the optimal
longitudinal view of the maximum IMT of each side was
recorded digitally. Then, after at least 20 min in relaxed
supine position, the M-mode scan of the left and right
common carotid artery (CCA) 10 mm proximal to the
origin of the carotid bulb was recorded simultaneously with
an electrocardiogram (ECG) for 20 s on S-VHS videotape.
By applying only minimal pressure, the sonographers took
care not to restrict the artery’s free movement. Blood
pressure was measured by a semiautomatic device (Di-
namap, Johnson & Johnson Medical, Arlington, Texas) at
three times during the M-mode examination. After 48
weeks, the entire examination was repeated, following the
same protocol and using the same angles of interrogation.
Sonographers (W. K. and P. A.) had completed a training
program with more than 1,000 scans of carotid arteries
before the trial. Periodically during the trial, recorded scans
were checked for visual quality by a panel comprising both
sonographers and one other investigator (S.S.).
Image analysis and calculation of CCA distensibility.
After the end of the trial a single reader evaluated the
digitized pictures of all M-mode scans. This person was
blinded with respect to identity of the subject, temporal
order of the scans and group assignment. All studies were
read in random order. Systolic and end-diastolic diameters
through three cardiac cycles were measured twice by means
of NIH-image 1.52 (public domain software, National
Institutes of Health, Bethesda, Maryland) on a Power
Macintosh 8100/80 with a high-resolution screen. All
diameter measurements of one artery were averaged, as were
brachial blood pressure measurements. Distensibility was







where DC is distensibility coefficient, Dd is diastolic diam-
eter, DD is difference between systolic and diastolic diam-
eter, and DP is pulse pressure. Distensibility of the left and
right CCA was averaged. A subject’s distensibility was
calculated only if both carotid arteries were visualized in
sufficient quality over three cardiac cycles. Maximum IMT
of the far wall of the CCA was measured from the digital
image. Each measurement was done twice and averaged. All
segments were read by one person (W.K.).
Following the same protocol, repeatability of DC mea-
surement was assessed in 23 women by additional ultra-
sound examination within one week after the follow-up
scan. As has been suggested (23), repeatability is expressed
as mean difference and standard deviation (SD) of the
difference between the DC measurements and was 1.9 6
7.2 3 1023/kPa. The correlation between replicate studies
was r 5 0.76.
Statistical analysis. For the outcome measures, both nor-
mality and homogeneity of variances were assessed by the
Lilliefors test and Levene test, respectively. Differences
between HRT 1 and no-HRT, and between HRT 2 and
no-HRT, were examined by independent sample t test or
chi-square test according to the nature of the data.
For analysis of the primary outcome measure, the p value
was adjusted for multiple comparisons according to the
Bonferroni-Holm method. For the secondary outcome
measures, no adjustment was made, because the analysis was
exploratory.
Change of distensibility within the treatment groups was
not defined as outcome measure; it was examined by
paired-samples t test in order to provide additional infor-
mation. Pearson correlation coefficient was used to examine
the relationship between baseline distensibility and other
baseline variables. Because randomization was stratified, in
additional analyses of the outcome measures the stratum
was controlled for by analysis of variance (ANOVA). All
calculations were performed on a Power Macintosh 7600/
120 using SPSS 6.1.1 (SPSS Inc., Chicago, Illinois).
At the start of the trial, no epidemiological data were
available for estimation of the effect of menopause or HRT
on CCA distensibility. Therefore, sample size was esti-
mated based on the assumption that the effect of HRT on
carotid artery distensibility would approximate the differ-
ence between a healthy person and someone with a mild
form of CHD. The ratio of SD to difference between the
means for normal and CHD subjects had been demon-
strated to be 1.6 for CCA distensibility (9). To obtain a
power of 90% and a p value of 0.05, 54 subjects were needed
in each group, plus 18 subjects to compensate for an
estimated 33% drop-out rate (24). Because preparatory
ultrasound examinations showed that M-mode scans meet-
ing the quality criteria of the protocol could not be obtained
in up to one third of the subjects, it was decided to perform
M-mode scans in all PHOREA subjects to ensure sufficient
statistical power.
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RESULTS
Baseline data. Randomization resulted in an even distri-
bution of baseline characteristics among treatment groups,
with the following exceptions: a family history of CHD was
more frequent in HRT 2 than in HRT 1, and in the
subgroup of smokers, LDL was lower in HRT 2 than in
no-HRT (Table 1).
Subjects who had a follow-up ultrasound examination
including distensibility measurement after 48 weeks (n 5
173), those who had complete IMT measurements, but in
whom distensibility measurement was not possible (n 5
91), and those who ended participation prematurely (n 5
57) did not differ with respect to the baseline characteristics
listed in Table 1 (data not shown, all p values . 0.2), with
the following exceptions: Subjects stopping the trial prema-
turely were more frequently current smokers (p 5 0.006).
Subjects with a complete set of DC measurements differed
from those without only with respect to lower weight and
body mass index (BMI; p 5 0.045 and p 5 0.027). Failure
to obtain distensibility measurements was due to technical
problems in 6 of these 91 subjects. In 85 subjects the
M-mode scan could not be obtained in the required quality:
in 31 subjects in both carotid arteries, and in 54 in one
carotid artery. In the majority of these cases visualization
was a problem at baseline and at follow-up examinations.
Among all variables listed in Table 1, smokers compared
to nonsmokers had lower BMI (24.1 6 3.4 vs. 25.9 6
4.3 kg/m2, p 5 0.037), lower FSH (53 6 14 vs. 62 6
30 IU/liter, p 5 0.019) and lower LDL (3.44 6 0.74 vs.
3.89 6 1.05 mmol/liter, p 5 0.052).
Distensibility at baseline was inversely correlated with age
(r 5 20.194, p 5 0.011), BMI (r 5 20.182, p 5 0.017),
blood glucose (r 5 20.149, p 5 0.053), LDL (r 5 20.189,
p 5 0.017) and IMT of the CCA (r 5 20.193, p 5 0.011).
Distensibility at baseline was not correlated with FSH
levels, nor with time of previous HRT use (36.7 6
51.7 months; mean 6 SD for all subjects). This was also
true in the subgroup of smokers. No difference in distensi-
bility was observed among present users of HRT (subjects
who used HRT until randomization), past users and never-
users of HRT.
Follow-up. After 48 weeks, distensibility did not change
significantly within groups (all p . 0.2), and change was not
significantly different between HRT groups and the no-
Table 1. Characteristics of All Subjects and of Smokers at Baseline
Characteristics













Age (yrs) 58.6 6 4.0 59.0 6 4.3 59.5 6 4.1 59.8 6 3.1 60.9 6 3.2 60.0 6 3.6
BMI (kg/m2) 25.9 6 4.2 25.5 6 4.1 25.6 6 4.4 23.3 6 4.1 25.1 6 3.8 23.8 6 2.9
Pack-years of cigarettes 28.6 6 22.8 26.3 6 25.0 22.8 6 21.0 51.3 6 15.0 44.6 6 24.7 29.5 6 26.4
Physical activity (hours/week) 1.6 6 2.5 2.0 6 2.4 2.3 6 2.8 2.8 6 3.8 0.6 6 0.7 1.8 6 1.7
Family history of CHD 21 (36.8%) 36 (59.0%) 27 (50.0%) 1 (50%) 4 (20%) 6 (50%)
Diabetes mellitus 3 (5.2%) 2 (3.3%) 5 (9.3%) 0 1 (12.5%) 2 (16.7%)
Hypertension 20 (34.5%) 28 (45.9%) 21 (38.9%) 1 (16.7%) 6 (75%) 7 (58.3%)
Current smokers 9 (15.5%) 10 (16.4%) 11 (20.4%) 6 8 12
CHD 1 (1.7%) 1 (1.6%) 5 (9.3%) 0 0 1 (8.3%)
Antihypertensive medication 15 (25.9%) 21 (34.4%) 17 (31.5%) 0 4 (50%) 4 (33%)
Lipid-lowering medication 4 (6.9%) 4 (6.6%) 5 (9.3%) 0 0 1 (8.3%)
Glucose (mmol/liter) 5.7 6 2.6 5.7 6 1.1 6.4 6 3.4 5.2 6 0.5 6.0 6 1.3 6.2 6 1.7
LDL (mmol/liter) 3.93 6 0.92 3.85 6 1.15 3.71 6 0.95 3.20 6 0.30 3.10 6 0.70* 3.83 6 0.78*
HDL (mmol/liter) 1.72 6 0.49 1.82 6 0.54 1.80 6 0.58 1.77 6 0.39 1.86 6 0.54 1.67 6 0.33
Triglycerides (mmol/liter) 2.38 6 3.22 1.78 6 1.17 2.08 6 1.27 1.38 6 0.94 1.59 6 0.84 2.55 6 1.46
Fibrinogen (g/liter) 2.85 6 0.49 2.88 6 0.59 2.70 6 0.68 2.79 6 0.27 3.22 6 0.81 2.67 6 0.74
Follicle stimulating hormone
(IU/liter)
62 6 26 61 6 33 57 6 26 52 6 9 48 6 12.7 55 6 16
Systolic BP (mm Hg) 152.5 6 23.5 153.5 6 26.2 153.8 6 25.8 156.9 6 27.4 156.1 6 40.9 150.1 6 23.4
Diastolic BP (mm Hg) 87.9 6 13.3 85.7 6 12.2 88.3 6 15.3 82.5 6 10.8 83.9 6 16.2 84.6 6 11.9
Pulse pressure (mm Hg) 64.6 6 14.8 67.8 6 19.0 65.5 6 16.2 74.4 6 18.7 72.2 6 25.3 65.5 6 14.7
Pulse rate (beats/min) 70 6 9 70 6 10 72 6 11 73 6 7 70 6 8 73 6 14
IMT of CCA (mm) 1.1 6 0.2 1.0 6 0.3 1.0 6 0.2 1.1 6 0.2 1.0 6 0.3 1.0 6 0.2
Diastolic diameter of CCA
(mm)
6.92 6 0.78 6.86 6 0.65 6.91 6 0.75 7.51 6 1.10 7.08 6 0.75 6.77 6 0.61
Difference between systolic
and diastolic diameter of
CCA (mm)
0.71 6 0.20 0.74 6 0.19 0.74 6 0.18 0.70 6 0.10 0.76 6 0.14 0.73 6 0.13
Distensibility (DC) of CCA
(31023/kPa)
25.7 6 11.4 26.2 6 11.9 25.9 6 7.9 20.8 6 7.9 25.3 6 11.9 25.9 6 7.5
Values are means 6 SD or numbers (percent), respectively.
p Values for differences between treatment groups are .0.05 unless otherwise indicated: *HRT 2 vs. no-HRT: p 5 0.049.
BMI 5 body mass index; BP 5 blood pressure; CHD 5 coronary heart disease; DC 5 distensibility coefficient; HDL 5 high-density lipoprotein cholesterol; HRT 5
hormone replacement therapy; LDL 5 low-density lipoprotein cholesterol; IMT 5 intima-media thickness; CCA 5 common carotid artery.
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HRT group (Table 2). Fibrinogen, LDL, and FSH de-
creased in both HRT groups but increased in the no-HRT
group, with a significant difference in changes among
groups (Table 2).
By contrast, in the small subgroup of 26 smokers,
distensibility did not change significantly in the HRT 1 and
the no-HRT group, but increased in the low-progestin
HRT 2 group by 32% (within-group p 5 0.086; between
HRT 2 and no-HRT: p 5 0.025) (Table 3, Fig. 2). In both
HRT groups, there was an increase in LDL, and the
decreases in fibrinogen and FSH were smaller than the
decrease observed in the entire sample, the changes not
being significantly different among the groups (Table 3).
In the three other subgroups defined by increased LDL
(.3.7 mmol/liter, n 5 81)—increased blood pressure
(.140 systolic or 90 diastolic, n 5 78), and age over 59 (n 5
74)—the change in distensibility was not significantly dif-
ferent among groups (all p . 0.2).
Because randomization was stratified, an additional anal-
ysis controlling for the stratum was conducted. Results












D Distensibility of CCA
(DC) (31023/kPa)*
0.2 6 11.6 0.9 6 11.7 20.2 6 10.4 p . 0.2 p . 0.2
D Diastolic diameter of
CCA (mm)
0.01 6 0.57 0.02 6 0.40 0.01 6 0.53 p . 0.2 p . 0.2
D Difference between systolic
and diastolic diameter of
CCA (mm)
0.02 6 0.22 0.00 6 0.26 0.03 6 0.22 p . 0.2 p . 0.2
D IMT of CCA (mm)* 0.03 6 0.07 0.02 6 0.06 0.01 6 0.07 p . 0.2 p . 0.2
D Weight (kg)* 20.1 6 2.6 20.4 6 4.3 0.8 6 3.6 p 5 0.138 p 5 0.134
D Systolic BP (mm Hg)* 27.9 6 24.2 27.0 6 22.7 28.4 6 23.0 p . 0.2 p . 0.2
D Diastolic BP (mm Hg)* 26.0 6 11.8 23.7 6 12.6 26.3 6 12.3 p . 0.2 p . 0.2
D Pulse pressure (mm Hg)* 21.9 6 16.6 23.3 6 15.0 22.1 6 14.8 p . 0.2 p . 0.2
D Glucose (mmol/liter)† 20.1 6 1.7 20.1 6 0.9 20.4 6 2.8 p . 0.2 p . 0.2
D LDL (mmol/liter)† 20.32 6 0.61 20.27 6 0.71 0.04 6 0.60 p 5 0.004 p 5 0.020
D HDL (mmol/liter)† 20.04 6 0.27 20.02 6 0.29 20.12 6 0.22 p 5 0.101 p 5 0.048
D Triglycerides (mmol/liter)† 20.23 6 2.39 20.04 6 0.92 0.06 6 1.05 p . 0.2 p . 0.2
D Fibrinogen (g/liter)† 20.23 6 0.44 20.21 6 0.45 0.03 6 0.48 p 5 0.005 p 5 0.009
D Follicle stimulating
hormone (IU/liter)†
222 6 30 219 6 25 7 6 24 p , 0.001 p , 0.001
*Follow-up value at 48 weeks minus baseline value; †mean follow-up values at 12, 22, and 48 weeks minus baseline value.
CCA 5 common carotid artery; BP 5 blood pressure; DC 5 distensibility coefficient; HDL 5 high-density lipoprotein cholesterol; HRT 5 hormone replacement therapy;
IMT 5 intima media thickness; LDL 5 low-density lipoprotein cholesterol.












D Distensibility of CCA
(DC) (31023/kPa)*
0.6 6 6.0 8.2 6 11.7 21.8 6 6.8 p . 0.2 p 5 0.025
D Diastolic diameter of
CCA (mm)
0.00 6 0.67 20.09 6 0.41 0.15 6 0.36 p . 0.2 p 5 0.182
D Difference between systolic
and diastolic diameter of
CCA (mm)
20.03 6 0.12 0.07 6 0.24 20.08 6 0.17 p . 0.2 p 5 0.128
D IMT of CCA (mm)* 0.03 6 0.09 0.01 6 0.04 0.00 6 0.07 p . 0.2 p . 0.2
D Weight (kg)* 1.5 6 1.4 22.6 6 7.5 20.4 6 1.9 p 5 0.046 p . 0.2
D Systolic BP (mm Hg)* 26.0 6 13.1 213.4 6 28.2 22.7 6 24.8 p . 0.2 p . 0.2
D Diastolic BP (mm Hg)* 20.6 6 9.7 25.5 6 14.7 0.4 6 11.0 p . 0.2 p . 0.2
D Pulse pressure (mm Hg)* 25.4 6 5.2 28.0 6 15.5 23.1 6 16.6 p . 0.2 p . 0.2
D Glucose (mmol/liter)† 0.1 6 0.7 0.0 6 0.4 20.2 6 1.5 p . 0.2 p . 0.2
D LDL (mmol/liter)† 0.23 6 0.35 0.12 6 0.86 20.08 6 0.51 p . 0.2 p . 0.2
D HDL (mmol/liter)† 0.02 6 0.32 0.02 6 0.24 20.15 6 0.17 p 5 0.155 p 5 0.076
D Triglycerides (mmol/liter)† 0.24 6 1.21 0.27 6 0.27 20.38 6 1.16 p . 0.2 p 5 0.086
D Fibrinogen (g/liter)† 20.08 6 0.25 20.11 6 0.37 0.25 6 0.60 p . 0.2 p 5 0.160
D Follicle stimulating
hormone (IU/liter)†
23 6 9 25 6 5 1 6 18 p . 0.2 p . 0.2
*Follow-up value at 48 weeks minus baseline value.
†Mean follow-up values at 12, 22, and 48 weeks minus baseline value.
CCA 5 common carotid artery; BP 5 blood pressure; DC 5 distensibility coefficient; HDL 5 high-density lipoprotein cholesterol; HRT 5 hormone replacement therapy;
IMT 5 intima media thickness; LDL 5 low-density lipoprotein cholesterol.
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remained virtually unchanged with only the difference in
change of distensibility between HRT 2 and no-HRT in
smokers being significant (p 5 0.029), whereas all other
differences in change of distensibility among groups were
not significant (all p . 0.02).
Serious adverse events. One death occurred in the HRT 2
group owing to intracerebral bleeding in a patient with a
history of poorly controlled hypertension. Breast cancer was
diagnosed in one subject in the no-HRT group. There was
one hysterectomy in the no-HRT group. No incidents of
deep venous thrombosis or thromboembolism occurred;
there were no cases of myocardial infarction or ischemic
stroke.
DISCUSSION
Hormone replacement therapy did not alter CCA distensi-
bility after 48 weeks in postmenopausal women, with signs
of early atherosclerosis indicated by increased carotid artery
IMT, regardless whether a high or a low dose of progestin
was used. In the subgroup of smokers, but not in the other
three predefined subgroups, HRT with low-dose progestin
significantly improved CCA distensibility, whereas the im-
provement by high-progestin HRT was not significant.
Our results refute our hypothesis but are in line with
several previous studies—namely that no difference was
found between CCA DC of HRT users and nonusers (16).
Aortic size, but not aortic compliance, was influenced by
HRT in a small randomized trial (25). Pausing and recom-
mencing HRT changed pulse-wave velocity of peripheral,
but not of central, arteries (17). Recently published random-
ized trials (26–28) did not find the beneficial cardiovascular
effects of HRT that were suggested in earlier epidemiolog-
ical studies (20). Potential selection bias in epidemiological
research has been discussed (29).
Examining the discrepancy between the present random-
ized study and previous epidemiological studies (18,30), two
main issues should be considered. First, did our study miss
any relevant effect due to its sample size? Post hoc recalcu-
lation of the study power showed that under the given
conditions a difference in change of DC of 6.5 3 1023/kPa
corresponding to a difference of 25% could have been
detected with a power of 90% and a p , 0.05. This is
comparable to the a priori estimation. Stiffness was 21%
higher in nonusers than in users of HRT in one positive
study (18). The other positive study reported a 13% differ-
ence in stiffness between women with and without HRT,
and a 7% increase as early as after four weeks of HRT
withdrawal (30). Menopause caused a 33% decrease in
aortic root distensibility within three years at maximum
(11). A maximum effect of 3% increase was observed in the
present study. Thus, it seems unlikely that we would have
missed a change of the magnitude previously observed.
The second issue is the time of follow-up. In this study,
in the cross-sectional analysis at baseline, previous long-
term HRT was not related to CCA DC at the study start,
which may suggest that HRT over several years did not
influence CCA DC. The previously observed influence of
HRT on distensibility of large arteries appeared after a short
time: withdrawal of HRT changed aortic distensibility
within four weeks (30), and application of intravenous
estrogen changed it within 20 min (31). In peripheral
arteries, distensibility was found to increase until up to one
year (32). Thus, we would expect relevant effects to be
detectable within one year.
HRT and smoking. In this study, HRT with low-dose
progestin increased CCA DC in smokers by 32%. With
respect to the negative results of the HERS trial (27), our
finding indicates the possibility that selected subgroups of
postmenopausal women with elevated risk for CHD might
benefit from HRT. An epidemiological study with almost
identical methodology recently observed the same phenom-
enon (effect only in smokers) (16). Furthermore, higher
systemic arterial compliance, a measure of central conduit
artery mechanical properties, has been found in smokers on
HRT compared to smokers not on HRT, but not in
nonsmokers on HRT (19).
Smoking cigarettes reduces carotid artery distensibility by
up to 33% (33–35) in both long- and short-term. Sympa-
thetic activation, subsequent increase in arterial smooth
muscle tone and impaired endothelium-dependent vasodi-
lation may contribute to this phenomenon (33,34,36).
These changes may be counteracted by HRT (21,37), by
increased production of nitric oxide (38), by shifting auto-
nomic balance from sympathetic to vagal tone (39), by
increased gene expression for vasodilatory enzymes such as
prostacyclin synthase and nitric oxide synthase, by inhibited
proliferation of vascular smooth-muscle cells and by accel-
erated growth of endothelial cells (40).
The effects of progestin. As the present study indicates,
the beneficial effect of estrogen may be lost when progestin
is added to the HRT regimen. Progestin negated the
inhibitory effects of estrogen on coronary atherosclerosis in
a primate model, independent of any change in lipid profile
Figure 2. Change of distensibility by group in smokers. Boxes represent
means; size of boxes represents size of group; bars represent SEM. HRT 5
hormone replacement therapy.
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(41). The improvement of endothelial function observed
after both short-term and long-term application of estrogen
(21,37,42) was absent when a combined HRT regimen was
given (28). In a rabbit model, estrogen but not progestin
prevented collagen synthesis in the aorta of ovarectomized
animals (43). Observations in postmenopausal HRT users
showed beneficial effects on distensibility only when estro-
gen alone was given (14,16).
Study limitations. Both sample size and time of follow-up
have been discussed above. Furthermore, a beneficial effect
on distensibility was found only in a small subgroup pre-
defined as secondary outcome measure. Yet both the con-
sistency with previous investigations and the biological
plausibility corroborate the results. Certainly, a specifically
designed study is warranted.
Compared to B-mode IMT measurements, distensibility
measurements from M-mode were achieved in fewer sub-
jects, as was expected; the vessel wall near to the probe,
required only for DC calculation, was more difficult to
visualize than was the far wall. Subjects for whom valid
distensibility measurements could not be performed had
higher BMI but did not differ from subjects with distensi-
bility measurements in any other variable with a potential
influence on arterial distensibility. Still, although there is no
reason to a assume selection bias, we cannot exclude it.
Conclusions. In postmenopausal women who are at in-
creased risk for cardiovascular morbidity and mortality as
indicated by an increased carotid IMT, HRT did not alter
distensibility of the central arteries. In the context of other
randomized trials, especially those with clinical end points
(27), this casts doubt on the value of HRT in prevention of
cardiovascular diseases. The positive result in the subgroup
of smokers treated with estrogen and low-dose progestin
merits further study.
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